



Effective Health Care Mandatory FDA Reporting of Insulin Nomination Summary Document

Results of Topic Selection Process & Next Steps

- *Mandatory FDA reporting of insulin* does not fit within the domain of the Effective Health Care (EHC) Program because the topic does not address a specific therapeutic or diagnostic intervention. No further activity will be undertaken on this topic.

Topic Description

Nominator(s): Individual

Nomination Summary: The nominator is interested in requirements stipulating mandatory reporting of insulin pump malfunctions and related adverse events by health care professionals to the FDA or other regulatory agency.

Considerations

- The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews focus attention on the evidence from research studies about the effectiveness and safety of a clinical intervention.
- The topic does not meet EHC Program appropriateness criteria. (For more information, see <http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/how-are-research-topics-chosen/>.)